Education
About Us
Working with TipRanks
Follow Us
Erasca (ERAS)
NASDAQ:ERAS
ERAS Stock Chart & Stats
$3.17
-$0.05(-2.00%)
At close: 4:00 PM EST
$3.17
-$0.05(-2.00%)
Day’s Range― - ―
52-Week Range$1.01 - $3.30
Previous CloseN/A
Volume148.24K
Average Volume (3M)1.39M
Market Cap
$899.37M
Enterprise Value$378.32M
Total Cash (Recent Filing)$288.40M
Total Debt (Recent Filing)$48.29M
Price to Earnings (P/E)―
Beta1.83
Next Earnings
Mar 19, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding283,711,800
10 Day Avg. Volume1,680,213
30 Day Avg. Volume1,391,217
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)1.39
Price to Sales (P/S)0.00
P/FCF Ratio-5.36
Enterprise Value/Market Cap0.42
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-454.71
Enterprise Value/Ebitda-3.00
Forecast
1Y Price Target
$4.50Price Target Upside41.96% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.44
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial StabilityErasca has a healthy balance sheet with a cash runway extending beyond expected Phase 1 proof of concept data in 2026, indicating financial stability.
Intellectual PropertyERAS announced issuance of composition of matter patent for lead pan-RAS program, providing patent protection until at least September 2043.
Market PotentialThe large total addressable market for pan-RAS inhibitors provides an opportunity for Erasca to be highly successful as a second mover.
Bears Say
Competitive ChallengesErasca faces an increasingly competitive market for molecular glue assets, leading to a reduction in peak market share expectations for its key assets.
Growth PotentialErasca's melanoma drug naporafenib is unlikely to find a partner for development, impacting its growth potential.
Market PositioningA significant amount of spending and time is required to evaluate combination options and earlier lines of therapy, with Erasca several years behind competitors.
Erasca News
ERAS FAQ
What was Erasca’s price range in the past 12 months?
Erasca lowest stock price was $1.01 and its highest was $3.30 in the past 12 months.
What is Erasca’s market cap?
Erasca’s market cap is $899.37M.
When is Erasca’s upcoming earnings report date?
Erasca’s upcoming earnings report date is Mar 19, 2026 which is in 107 days.
How were Erasca’s earnings last quarter?
Erasca released its earnings results on Nov 12, 2025. The company reported -$0.11 earnings per share for the quarter, missing the consensus estimate of -$0.104 by -$0.006.
Is Erasca overvalued?
According to Wall Street analysts Erasca’s price is currently Undervalued.
Does Erasca pay dividends?
Erasca does not currently pay dividends.
What is Erasca’s EPS estimate?
Erasca’s EPS estimate is -0.11.
How many shares outstanding does Erasca have?
Erasca has 283,711,800 shares outstanding.
What happened to Erasca’s price movement after its last earnings report?
Erasca reported an EPS of -$0.11 in its last earnings report, missing expectations of -$0.104. Following the earnings report the stock price went down -4.151%.
Which hedge fund is a major shareholder of Erasca?
Currently, no hedge funds are holding shares in ERAS
Erasca Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.50 (41.96% Upside)
$4.50 (41.96% Upside)
Blogger Sentiment
Bullish
ERAS Sentiment 100%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Decreased
By 541.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 8.2%
Last 30 Days ▼ 8.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
8.56%
12-Months-Change
Fundamentals
Return on Equity
-32.00%
Trailing 12-Months
Asset Growth
-20.51%
Trailing 12-Months
Company Description
Erasca
Erasca, Inc. (ERAS) is a clinical-stage biopharmaceutical company focused on discovering and developing novel oncology therapies. The company aims to eradicate cancer by targeting biological drivers of the disease using precision medicine approaches. Erasca is working on a pipeline of small molecule drugs designed to inhibit oncogenic signaling pathways and address unmet needs in cancer treatment.
ERAS Stock 12 Month Forecast
Average Price Target
$4.50
▲(41.96% Upside)
Technical Analysis
Arcturus Therapeutics
―
Arvinas Holding Company
―
Opthea Limited Sponsored ADR
―
Olema Pharmaceuticals
―
Bicara Therapeutics Inc.
―
Ownership Overview
12.38% Insiders
11.25% Mutual Funds
54.63% Other Institutional Investors
13.79% Public Companies and
Individual Investors